The U.S. Department of Commerce last Friday announced new anti-dumping duties on solar products from Cambodia, Malaysia, Thailand, and Vietnam, with rates as high as 271.2%. The move appears to target Chinese photovoltaic companies that set up factories in those countries to avoid similar duties on their China made-products, and now many are closing those Southeast Asian facilities as a result.

According to the announcement from the U.S. International Trade Commission (USITC), the tariffs mainly target panels and their components made in Cambodia, Malaysia, Thailand and Vietnam with anti-dumping duties from 0% to 271.2%, depending on the producer and specific country.

Currently, about 80% of solar panels imported into the U.S. come from the four Southeast Asian countries. The new tariffs are expected to further affect the global solar industry’s supply chain, encouraging more production to shift to the U.S., gradually replacing imports.

Caixin reported that a number of Chinese solar companies have already shut down their factories in Southeast Asia. Some industry insiders said that setting up factories in the U.S. may be the only viable option for them. While construction and labor costs are higher, gross margins are also higher for panels sold in the U.S., and the market also has greater potential. Furthermore, the U.S. can also serve as a hub for exporting products to other markets.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…